Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Mai 2016 16:05 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications

All Hematological Malignancies Targeted by KTE-C19 Development Now Covered by Orphan Drug Designations in U.S. and EU SANTA MONICA, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc....
28. April 2016 07:00 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Announces Presentations at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

SANTA MONICA, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) ("Kite") a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell...
19. April 2016 16:05 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting

SANTA MONICA, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) ("Kite") today announced updated clinical results from the phase 1 portion of Kite's ZUMA-1 trial of its lead...
18. April 2016 16:05 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Commends Scientific Advisory Board Members on Awards Received from the American Association of Cancer Research (AACR)

Antoni Ribas, M.D., Ph.D. and Ronald Levy, M.D. recognized for their major contributions to cancer research SANTA MONICA, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc....
16. April 2016 14:15 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Announces Review of National Cancer Institute’s Manufacturing Facilities

- Kite’s four ongoing multi-center clinical trials of its lead product candidate, KTE-C19, are continuing - - Kite remains on track to file an investigational new drug application (IND) with the Food...
15. April 2016 20:06 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Announces Key Presentations on KTE-C19 and Engineered Cell Therapy Pipeline Programs at the Annual Meeting of the American Association for Cancer Research (AACR)

SANTA MONICA, Calif., April 15, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) ("Kite") a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell...
17. März 2016 08:00 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Announces Clinical Collaboration to Evaluate Two Novel Immunotherapies for Patients with Non-Hodgkin Lymphoma

SANTA MONICA, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has entered into a clinical trial collaboration with Genentech, a member of the Roche...
16. März 2016 16:54 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research (AACR)

SANTA MONICA, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) (“Kite”) a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell...
16. März 2016 07:30 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Deepens Cell Manufacturing and Operations Expertise with Appointment of Tim Moore

SANTA MONICA, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced the appointment of Tim Moore as Executive Vice President, Technical Operations. With more...
03. März 2016 16:55 ET | Quelle: Kite Pharma, Inc.

Kite Pharma to Present at March 2016 Investor Conferences

SANTA MONICA, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that management will present at two investor conferences in March:Cowen and Company...

Nächste Seite